CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025
CorMedix (Nasdaq: CRMD), a biopharmaceutical company developing therapeutic products for life-threatening diseases, has scheduled its first quarter 2025 financial results announcement for May 6, 2025, before market opening.
The company will host a corporate update conference call at 8:30am Eastern Time on the same day. Interested parties can join through:
- Domestic call-in: 1-844-676-2922
- International call-in: 1-412-634-6840
- Conference ID: 10198548
- Webcast available via provided link
CorMedix (Nasdaq: CRMD), un'azienda biofarmaceutica che sviluppa prodotti terapeutici per malattie potenzialmente letali, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per il 6 maggio 2025, prima dell'apertura dei mercati.
La società terrà una conference call di aggiornamento aziendale alle 8:30 ora della costa orientale dello stesso giorno. Gli interessati possono partecipare tramite:
- Numero nazionale: 1-844-676-2922
- Numero internazionale: 1-412-634-6840
- ID conferenza: 10198548
- Webcast disponibile tramite il link fornito
CorMedix (Nasdaq: CRMD), una compañía biofarmacéutica que desarrolla productos terapéuticos para enfermedades potencialmente mortales, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el 6 de mayo de 2025, antes de la apertura del mercado.
La compañía realizará una llamada de actualización corporativa a las 8:30 am hora del Este el mismo día. Los interesados pueden unirse a través de:
- Teléfono nacional: 1-844-676-2922
- Teléfono internacional: 1-412-634-6840
- ID de conferencia: 10198548
- Transmisión web disponible mediante el enlace proporcionado
CorMedix (나스닥: CRMD), 생명을 위협하는 질병에 대한 치료 제품을 개발하는 생명공학 제약 회사는 2025년 1분기 재무 실적 발표를 2025년 5월 6일 시장 개장 전에 예정하고 있습니다.
회사는 같은 날 동부 표준시 오전 8시 30분에 기업 업데이트 컨퍼런스 콜을 진행합니다. 관심 있는 분들은 다음 방법으로 참여할 수 있습니다:
- 국내 전화 연결: 1-844-676-2922
- 국제 전화 연결: 1-412-634-6840
- 컨퍼런스 ID: 10198548
- 제공된 링크를 통한 웹캐스트 이용 가능
CorMedix (Nasdaq : CRMD), une société biopharmaceutique développant des produits thérapeutiques pour des maladies potentiellement mortelles, a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le 6 mai 2025, avant l'ouverture du marché.
La société tiendra une conférence téléphonique de mise à jour corporative à 8h30, heure de l'Est le même jour. Les personnes intéressées peuvent participer via :
- Appel national : 1-844-676-2922
- Appel international : 1-412-634-6840
- ID de conférence : 10198548
- Webcast disponible via le lien fourni
CorMedix (Nasdaq: CRMD), ein biopharmazeutisches Unternehmen, das therapeutische Produkte für lebensbedrohliche Krankheiten entwickelt, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für den 6. Mai 2025 vor Börsenöffnung geplant.
Das Unternehmen wird am selben Tag um 8:30 Uhr Eastern Time eine Telefonkonferenz zur Unternehmensaktualisierung abhalten. Interessierte können über folgende Wege teilnehmen:
- Inländische Einwahlnummer: 1-844-676-2922
- Internationale Einwahlnummer: 1-412-634-6840
- Konferenz-ID: 10198548
- Webcast über den bereitgestellten Link verfügbar
- Timely financial reporting compliance with scheduled Q1 2025 results announcement
- Management's proactive investor communication through scheduled conference call
- None.
BERKELEY HEIGHTS, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the first quarter ended March 31, 2025, before the market opens on Tuesday, May 6, 2025, and will host a corporate update conference call at 8:30am Eastern Time.
| Tuesday, May 6th @ 8:30am ET | |
| Domestic: | 1-844-676-2922 |
| International: | 1-412-634-6840 |
| Conference ID: | 10198548 |
| Webcast: | Webcast Link |
About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix is commencing clinical studies in Total Parenteral Nutrition and Pediatric patient populations in 2025 and also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com.
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
FAQ
When will CorMedix (CRMD) release Q1 2025 financial results?
How can investors join the CorMedix (CRMD) Q1 2025 earnings call?
What time is the CorMedix (CRMD) Q1 2025 earnings conference call?
What will CorMedix (CRMD) discuss in their May 6 conference call?
What is the international dial-in number for CRMD's Q1 2025 earnings call?
